We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MURA Mural Oncology PLC

0.26 (7.2%)
Dec 02 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 783,923
Bid Price 3.65
Ask Price 3.87
News -
Day High 3.87


52 Week Range


Day Low 3.51
Company Name Stock Ticker Symbol Market Type
Mural Oncology PLC MURA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.26 7.2% 3.87 00:00:05
Open Price Low Price High Price Close Price Prev Close
3.56 3.51 3.87 3.66 3.61
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,934 783,923 $ 3.61 $ 2,832,469 - 3.40 - 17.00
Last Trade Time Type Quantity Stock Price Currency
19:43:30 1 $ 3.70 USD

Mural Oncology PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 64.58M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Mural Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MURA Message Board. Create One! See More Posts on MURA Message Board See More Message Board Posts

Historical MURA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.554.253.503.76926,8090.329.01%
1 Month16.6917.003.404.061,496,904-12.82-76.81%
3 Months16.6917.003.404.061,496,904-12.82-76.81%
6 Months16.6917.003.404.061,496,904-12.82-76.81%
1 Year16.6917.003.404.061,496,904-12.82-76.81%
3 Years16.6917.003.404.061,496,904-12.82-76.81%
5 Years16.6917.003.404.061,496,904-12.82-76.81%

Mural Oncology Description

Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |